Trial Profile
BrUOG 299: Ixazomib, Oral Metronomic Cyclophosphamide and Dexamethasone for First-Line Treatment of Multiple Myeloma: A Phase II Brown University Oncology Group Study.
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 26 May 2023
Price :
$35
*
At a glance
- Drugs Ixazomib (Primary) ; Cyclophosphamide; Dexamethasone
- Indications Multiple myeloma
- Focus Therapeutic Use
- Acronyms BrUOG 299
- 08 May 2023 Results published in the Oncologist
- 30 Apr 2021 Planned End Date changed from 1 Sep 2019 to 1 Sep 2024.
- 07 Apr 2019 Status changed from recruiting to active, no longer recruiting.